Thoratec Takes Over Development Of Terumo’s DuraHeart II VAD
This article was originally published in The Gray Sheet
Executive Summary
Thoratec paid $13 million plus future milestone commitments worth up to $43.5 million for the next-generation ventricular assist technology, which it hopes will be ready for human implants by 2016.
You may also be interested in...
HeartWare Touts Early Success In U.S. Launch Of HVAD
HeartWare sold 134 HVAD ventricular assist systems in the U.S. following FDA approval in November and continues to rapidly add more centers to its customer base.
Pressure Builds In Ventricular Assist Market
With only two companies, Thoratec and HeartWare International, selling LVADs in the US, clinical data along with sales and product pipeline strategies have become paramount for capturing market share – and expanding the market to treat a wide range of class III heart failure patients.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.